Literature DB >> 24308364

Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.

Mohammad H El-Dakdouki1, Jingguang Xia, David C Zhu, Herbert Kavunja, Jessica Grieshaber, Sandra O'Reilly, J Justin McCormick, Xuefei Huang.   

Abstract

Magnetic nanoparticles are attractive platforms for biomedical applications including diagnosis and treatment of diseases. We have shown previously that hyaluronan-coated superparamagnetic iron oxide nanoparticles (HA-SPIONs) enhanced the efficacy of the conjugated anticancer drug doxorubicin (DOX) in vitro against drug-sensitive and drug-resistant human ovarian cancer cells. In this manuscript, we report our findings on the efficacy of DOX loaded HA-SPIONs in vivo using subcutaneous and intraperitoneal SKOV-3 ovarian tumor models in nude mice. The accumulation of the nanoparticles in subcutaneous tumors following an intravenous nanoparticle administration was confirmed by magnetic resonance imaging, and its distribution in the tumors was evaluated by confocal microscopy and Prussian blue staining. DOX delivered by nanoparticles accumulated at much higher levels and distributed wider in the tumor tissue than intravenously injected free DOX, leading to significant reduction of tumor growth. The IVIS Spectrum for in vivo bioluminescence imaging was used to aid in therapy assessment of the DOX-loaded nanoparticles on intraperitoneal ovarian tumors formed by firefly luciferase expressing human ovarian SKOV-3 cells. DOX-loaded HA-SPIONs significantly reduced tumor growth, delayed tumor development, and extended the survival of mice. Thus, utilizing HA-SPIONs as drug delivery vehicles constitutes a promising approach to tackle CD44 expressing ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308364      PMCID: PMC3912576          DOI: 10.1021/am404946v

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  48 in total

1.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

2.  Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages.

Authors:  Medha Kamat; Kheireddine El-Boubbou; David C Zhu; Teri Lansdell; Xiaowei Lu; Wei Li; Xuefei Huang
Journal:  Bioconjug Chem       Date:  2010-10-26       Impact factor: 4.774

Review 3.  Strategies to examine new compounds for intraperitoneal use in ovarian cancer.

Authors:  M Markman
Journal:  Int J Gynecol Cancer       Date:  2008 Mar-Apr       Impact factor: 3.437

Review 4.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 5.  Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents.

Authors:  Nohyun Lee; Taeghwan Hyeon
Journal:  Chem Soc Rev       Date:  2011-12-02       Impact factor: 54.564

6.  Magnetic glyco-nanoparticles: a tool to detect, differentiate, and unlock the glyco-codes of cancer via magnetic resonance imaging.

Authors:  Kheireddine El-Boubbou; David C Zhu; Chrysoula Vasileiou; Babak Borhan; Davide Prosperi; Wei Li; Xuefei Huang
Journal:  J Am Chem Soc       Date:  2010-03-31       Impact factor: 15.419

Review 7.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

8.  Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures.

Authors:  Mohammad H El-Dakdouki; Ellen Puré; Xuefei Huang
Journal:  Nanoscale       Date:  2013-03-26       Impact factor: 7.790

9.  Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.

Authors:  Ignace Vergote; Frederic Amant; Karin Leunen; Isabelle Cadron; Toon Van Gorp; Patrick Neven; Patrick Berteloot
Journal:  Oncologist       Date:  2008-04

10.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Authors:  A Poveda; I Vergote; S Tjulandin; B Kong; M Roy; S Chan; E Filipczyk-Cisarz; H Hagberg; S B Kaye; N Colombo; C Lebedinsky; T Parekh; J Gómez; Y C Park; V Alfaro; B J Monk
Journal:  Ann Oncol       Date:  2010-07-19       Impact factor: 32.976

View more
  13 in total

Review 1.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.

Authors:  Seyed Mohammadali Dadfar; Karolin Roemhild; Natascha I Drude; Saskia von Stillfried; Ruth Knüchel; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2019-01-11       Impact factor: 15.470

Review 2.  Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery.

Authors:  Jeannine M Coburn; David L Kaplan
Journal:  Bioconjug Chem       Date:  2015-03-02       Impact factor: 4.774

3.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

4.  Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.

Authors:  Seyedmehdi Hossaini Nasr; Zahra Rashidijahanabad; Sherif Ramadan; Nate Kauffman; Narayanan Parameswaran; Kurt R Zinn; Chunqi Qian; Ripla Arora; Dalen Agnew; Xuefei Huang
Journal:  Nanoscale       Date:  2020-05-07       Impact factor: 7.790

Review 5.  Hyaluronan as a therapeutic target in human diseases.

Authors:  Jiurong Liang; Dianhua Jiang; Paul W Noble
Journal:  Adv Drug Deliv Rev       Date:  2015-11-02       Impact factor: 15.470

6.  Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.

Authors:  Hai Wang; Pranay Agarwal; Shuting Zhao; Ronald X Xu; Jianhua Yu; Xiongbin Lu; Xiaoming He
Journal:  Biomaterials       Date:  2015-08-29       Impact factor: 12.479

7.  A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected].

Authors:  Hai Wang; Pranay Agarwal; Shuting Zhao; Jianhua Yu; Xiongbin Lu; Xiaoming He
Journal:  Nat Commun       Date:  2015-12-01       Impact factor: 14.919

8.  Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.

Authors:  You-Sin Jian; Ching-Wen Chen; Chih-An Lin; Hsiu-Ping Yu; Hua-Yang Lin; Ming-Yuan Liao; Shu-Huan Wu; Yan-Fu Lin; Ping-Shan Lai
Journal:  Int J Nanomedicine       Date:  2017-03-27

Review 9.  Targeting hyaluronic acid family for cancer chemoprevention and therapy.

Authors:  Vinata B Lokeshwar; Summan Mirza; Andre Jordan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

Review 10.  The Role of CD44 in Disease Pathophysiology and Targeted Treatment.

Authors:  Andre R Jordan; Ronny R Racine; Martin J P Hennig; Vinata B Lokeshwar
Journal:  Front Immunol       Date:  2015-04-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.